Industry

Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma

-Top line data expected in second half of 2023- ROCKVILLE, Md.–(BUSINESS WIRE)–#MCC–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced dosing of the first patient in the company’s Phase 1 study evaluating ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with … [Read more…]

STAAR Surgical to Report Second Quarter Results on August 10, 2022

LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close. STAAR will host a conference call … [Read more…]

Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma

FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #AAD–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s risk stratification gene expression profile (GEP) test, at the 2022 American Academy of Dermatology (AAD) Innovation Academy, being held in Vancouver, Canada, July 21-24. DecisionDx-Melanoma is designed … [Read more…]

Healthcare Services Group, Inc. Reports Q2 2022 Results

BENSALEM, Pa.–(BUSINESS WIRE)–Healthcare Services Group, Inc. (NASDAQ:HCSG) (the “Company”) reported for the three months ended June 30, 2022 revenue of $424.9 million and net income of $6.8 million, or $0.09 per basic and diluted common share. The Company’s Board of Directors declared a quarterly cash dividend of $0.21375 per common share, the 76th consecutive increase … [Read more…]

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction

HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT). CDR132L is an oligonucleotide-based … [Read more…]

Cherry Labs Awarded NIH Grant to Help Older Americans Age in Place Independently Using Privacy-protected, AI-based Monitoring

Mom and Dad Want Independence and Peace of Mind at Home? Cherry And NIH Study To Help REDWOOD CITY, Calif.–(BUSINESS WIRE)–Cherry Labs today announced they received a grant from the National Institutes of Health (NIH) and are embarking on a study to help maintain independence for older adults using their AI-driven Cherry Home technology. Cherry … [Read more…]

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

New data emphasizes the utility of the VeriStrat® Proteomic Test to identify patients likely to benefit from Immune Checkpoint Inhibitors BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and Oncology) … [Read more…]

CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic

– Proceeds to Support Clinical Development of Lead CNS & Liver Programs; IND for Dravet Syndrome is Anticipated by Mid-2023 – New Capital Will Also Fuel Expansion of CAMP4’s regRNA Actuating Platform™, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression – Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square … [Read more…]

6-Hour Virtual Seminar on Master Class for the HIPAA Officer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “6-Hour Virtual Seminar on Master Class for the HIPAA Officer: Protecting Patient Information and Implementing Today’s Privacy, Security, and Breach Regulations” webinar has been added to ResearchAndMarkets.com’s offering. Overview: The session begins with overview of the HIPAA regulations and then continues with presentation of the specifics of the Privacy Rule, such as Individual … [Read more…]